Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
Background/Aims Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks...
Main Authors: | Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi, Byoung Whui Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Association of Internal Medicine
2021-07-01
|
Series: | The Korean Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.kjim.org/upload/pdf/kjim-2020-549.pdf |
Similar Items
-
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
by: Jae-Woo Jung, et al.
Published: (2021-09-01) -
Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study
by: Anna Sztafińska, et al.
Published: (2017-10-01) -
Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01) -
Omalizumab for chronic rhinosinusitis
by: Rocío Brañes, et al.
Published: (2018-11-01) -
Cytomegalic hepatitis in a patient receiving omalizumab
by: R. Gonçalves, et al.
Published: (2016-01-01)